



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 6th 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**
 - Updates

- **Medical Director Update** **6:40 – 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- **Follow-up Items from Previous Meetings** **6:45 – 6:45**

- **RetroDUR/DUR** **6:45 – 6:55**
 - Introduce: Methadone use after Prior Authorization Implementation

- **Review of Newly-Developed/Revised** **6:55 – 7:40**

(Public comment prior to Board action)
 - ADHD and Cataplexy Medications: Miscellaneous (1/1/17)
 - Anticoagulants: Injectable (1/1/17)
 - Anti-hypertensives: ARB, ARB/CCB Combo (1/1/17)
 - Anti-infective: Cephalosporins 3rd Generation (1/1/17)
 - Epinephrine Auto Injector (1/1/17)
 - Gout Agents (1/1/17)
 - Hepatitis C Agents (1/1/17)
 - Lipotropics: Fibric Acid Derivatives (1/1/17)
 - Ophthalmic: Antibiotics, Antihistamines, Topical Corticosteroids, Glaucoma Agents, NSAID's (1/1/17)
 - Renal Disease: Phosphate Binders (1/1/17)
 - Urinary Antispasmodics (1/1/17)
 - Vaginal Anti-infective (1/1/17)

- **Clinical Update: Drug Reviews** **7:40 – 7:40**
(Public comment prior to Board action)

Abbreviated New Drug Reviews
 - None

Full New Drug Reviews

- Cinqair® Inj (reslizumab) (included in the Immunologic Therapies for Asthma Therapeutic Drug Class Review)
- Cholbam® Capsules (cholic acid) (included in the Bile Salts Therapeutic Drug Class Review)
- Ocliva® Tablets (obeticholic acid) (included in the Bile Salts Therapeutic Drug Class Review)

- **New Managed Therapeutic Drug Classes** **7:40-8:00**
(Public comment prior to Board action)
 - Immunologic Therapies for Asthma
 - Bile Salts and Biliary Agents

- **Therapeutic Drug Classes – Periodic Review** **8:00 – 8:25**
(Public comment prior to Board action)
 - Antivirals, Oral
 - H. Pylori
 - Antifungals, Oral
 - Botulinum Toxins

- **Review of Newly-Developed/Revised**
(Public comment prior to Board action)

- **General Announcements** **8:25 – 8:30**
Selected FDA Safety Alerts

FDA analyses conclude that Xarelto clinical trial results were not affected by faulty monitoring device

http://www.fda.gov/Drugs/DrugSafety/ucm524678.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement - Risks Associated With Abuse and Dependence

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm526151.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

- **Adjourn** **8:30**